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Abstract 
Liposomes are frequently used in cancer therapy to encapsulate and apply anticancer drugs. Here 
we show that a systemic treatment of mice bearing skin tumors with empty phosphatidylcholine 
liposomes (PCL) resulted in inhibition of tumor growth, which was similar to that observed with 
the synthetic bacterial lipoprotein and TLR1/2 agonist Pam3CSK4 (BLP). Both compounds led to 
a substantial decrease of macrophages in spleen and in the tumor-bearing skin. Furthermore, both 
treatments induced the expression of typical macrophage markers in the tumor-bearing tissue. As 
expected, BLP induced the expression of the M1 marker genes Cxcl10 and iNOS, whereas PCL, 
besides inducing iNOS, also increased the M2 marker genes Arg1 and Trem2. In vitro 
experiments demonstrated that neither PCL nor BLP influenced proliferation or survival of tumor 
cells, whereas both compounds inhibited proliferation and survival and increased the migratory 
capacity of bone marrow derived macrophages (BMDM). However, in contrast to BLP, PCL did 
not activate cytokine secretion and induced a different BMDM phenotype. Together, the data 
suggest that similar to BLP, PCL induce an antitumor response by influencing the tumor 
microenvironment, in particular by functional alterations of macrophages, however in a distinct 
manner from those induced by BLP.  
 
Précis 
Liposomes are used to apply anticancer drugs. Similar to bacterial lipoprotein (BLP), empty 
liposomes induce an antitumor response. This is accompanied by alteration of the macrophages 
phenotype, which is, however, distinct from that induced by BLP.  
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Introduction 
Liposomes are frequently used to encapsulate and apply drugs, because they both are considered 
nontoxic and protect the substances from immediate dilution or degradation [1]. Several 
laboratories have reported the use of liposomes as drug carriers in the treatment of cancer and as 
vaccine delivery systems. Intense research has already led to the commercialization of several 
liposome-based therapeutics. Doxil and Lipoplatin, for example, represent liposome-encapsulated 
doxorubicin and cisplatin, respectively, for systemic cancer therapy [1].  
Liposomes can be classified according to their lamellarity, size, charge and preparation method 
[1]. Neutral liposomes usually consist of phosphatidylcholine (PC). Inclusion of phospholipids, 
such as phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, phosphatidylserine (PS) 
and diacetylphosphate impart negative charges [2]. Positively charged lipids, such as 
phosphatidylethanolamine and derivatives thereof can be used to prepare cationic liposomes. 
Since they can interact with negatively charged nucleic acid molecules they are used as DNA or 
RNA delivery systems [3]. Other molecules frequently included into liposomes are cholesterol 
and α-tocopherol. Whereas cholesterol increases the physical stability of liposomes particularly 
in the presence of biological fluids such as plasma [2], α-tocopherol prevents liposome auto-
oxidation, thereby increasing their stability without inducing any toxicity [4]. Furthermore, the 
addition of polyethylene glycol (PEG)-modified lipids increases the liposome circulation time 
and pharmacological efficacy of encapsulated drugs [5].  
In contrast to other liposomes, PC liposomes (PCL) are thought to have no immunogenic activity 
[6]. In contrast to PS liposomes, PCL neither induced apoptosis of phagocytic cell lines [7] nor 
did they modulate inflammatory responses [8]. They also did not mimic the effects of apoptotic 
cells on macrophages, i.e. inducing the expression of prostaglandin E synthases [9]. However, 
some immune modulatory capacity of PCL has been recently discussed by Graeser and 
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colleagues who showed that empty PCL have antimetastatic activity in an orthotopic mouse 
model of pancreatic cancer [10]. The authors suggested that PCL may activate cellular signaling 
pathways involved in tumor defense mechanisms in macrophages or endothelial cells.  
Macrophages comprise a major population of tumor-infiltrating immune cells [11] and their role 
in cancer is controversially discussed. In most solid tumors, the existence of macrophages is 
advantageous for tumor growth and metastasis and the majority of studies have linked high 
macrophage numbers to reduced patient survival [12]. These macrophages generally have a so-
called M2-like phenotype (also known as “alternatively” activated macrophages), consistent with 
cancer-related inflammation. The polarization to the M2 phenotype occurs when macrophages 
are exposed to Th2 cytokines, such as IL-4, IL-13 and IL-10 [13,14]. On the other hand 
macrophages can also exert beneficial roles in cancer [15]. Thus, in vitro studies showed that 
“classically” activated macrophages can be cytotoxic to tumor cells but not to normal cells. 
Macrophages with such a M1 phenotype commit to a proinflammatory response profile upon 
exposure to the Th1 cytokine IFNγ or to pathogen-associated molecules such as bacterial 
lipopolysaccharide (LPS) or BLP, i.e. agonists for Toll-like receptor (TLR) 4 and 1/2, 
respectively. Therefore, macrophages probably can have contrasting roles in cancer depending on 
their phenotype (for review see [14]). Macrophage phenotypes can be identified by the 
expression of representative M1 and M2 genes. For example, iNOS and the C-X-C motif 
chemokine 10 (Cxcl10) are key effector molecules produced by M1 macrophages, whereas 
arginase 1 (Arg1) and Trem2 (triggering receptor expressed on myeloid cells 2) are typical M2 
markers [16]. 
We made the unexpected observation that systemic treatment of mice bearing basal cell 
carcinoma (BCC, which is a tumor of the skin) with PCL resulted in a significant tumor growth 
inhibition as compared to controls. Our analysis revealed that the antitumor effects of PCL were 
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similar to those of BLP that has been shown to inhibit tumor growth in mice and to modulate the 
activity of macrophages [17,18]. Furthermore, our data suggest that PCL can alter the function 
and phenotype of macrophages in a particular manner, which are distinct from those induced by 
BLP. These data should be considered when PCL are used as drug delivery systems in the 
diseased organism. 
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Material and Methods 
Preparation of empty liposomes  
For the preparation of 40 ml of conventional liposomes soy phosphatidylcholine (4.0 g, Epikuron 
200, Lukas Meyer, Hamburg, Germany), cholesterol (0.6 g, Fluka, Buchs, Switzerland) and D,L-
α-tocopherol (0.02 g, Merck, Darmstadt, Germany) corresponding to 1 : 0.3 : 0.01 mol parts were 
used.  The lipid mixture was solubilized in 20 ml of a physiologic phosphate buffer (20 mM, pH 
7.4) supplemented with mannitol (230 mM, PB-Man). The resulting multilamellar vesicles were 
freeze-thawed in three cycles of liquid nitrogen and water at 40° C, followed by repetitive (8x) 
filter extrusion through 400 nm and 200 nm membranes (Nuclepore, Sterico, Dietikon, 
Switzerland) using a Lipex extruder (Northern Lipids Inc., Burnaby, BC, Canada). Liposome size 
and homogeneity was measured with a Nicomp laser light scattering particle sizer (Nicomp 370, 
Sta. Barbara, CA, USA). Routinely prepared small unilamellar liposomes have a mean diameter 
of 135±55 nm [3,19].  
 
Animals and i.p. injection of PCL and BLP in mice 
 
Conditional PtchfloxfloxERT2+/- mice were randomized into 3 groups (n=5 per group). BCC were 
induced by intramuscular injection of 100 µg tamoxifen as described [20]. Fifteen days after 
tamoxifen-mediated BCC induction, the mice were injected intraperitoneally (i.p.) with PCL at a 
dose of 550 µg/kg mouse body weight, followed by 275 µg/kg for the subsequent doses every 
fourth day for 75 days. For this purpose the liposome stock solution was freshly thawed and 
diluted each time in PBS to obtain the desired dose in 120 µl for each animal. Control animals 
were i.p. injected with the respective volume of PBS. Mice were also treated i.p. with 25 µg BLP 
(from InvivoGen) per mouse dissolved in 120 µl PBS with the same treatment schedule as PCL. 
Animals were euthanized 24 h after the last dose, and spleen and skin were excised. Parts of each 
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tissue were either frozen and stored at -80o C until RNA isolation, or formalin-fixed and 
embedded in paraffin for immunohistological analyses. The remains of the tissues were used for 
FACS analyses (see below). All animals were treated and housed in accordance with the German 
animal protection law. 
 
Measurement of tumor size 
BCC size was measured on hematoxylin and eosin (H&E) stained sections using the area 
calculation tool of the software cellF (Olympus Soft Imaging Solutions GmbH; Germany).  
 
Cell culture experiments  
The murine BCC cell line ASZ001 was established from UV-induced BCC of Ptch mutant mice 
and maintained as described [21]. BMDMs were isolated from femurs of C57BL/6 wildtype mice 
as previously described in a slightly modified manner [22]. In short, the ends of each femur were 
cut off with a scissor and the marrow was flushed out with Pluznik medium (DMEM, 30 % L929 
conditioned medium containing CSF, 5 % horse-serum, 0.002 % ß-mercaptoethanol) that induces 
the differentiation of monocytes to macrophages. The single cell suspension was first grown in a 
coated cell culture dish. This allowed fibroblasts and other sessile cells to attach to the surface of 
the culture dish. After 24 h the medium containing mononuclear cells was collected by 
centrifugation for 10 min at 1200 rpm. The cells were resuspended in Pluznik medium and 
seeded in uncoated petri dishes. The medium was refreshed after three days and after 4 additional 
days the BMDM were ready to use for further experiments. 
 
For BrdU incorporation assays, 6000 ASZ001 or 8000 BMDM were seeded in each well of a 96-
well-plate. For AnnexinV stainings and cell cycle analyses 2.4 x 105 cells/well were seeded into 
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6-well-plates. After 24 h, the cells were washed and incubated for 72 h in medium, supplemented 
with 0.5 µg/ml PCL or 100 ng/ml BLP (this dose is usually applied to activate BMDMs in vitro 
[23], or the respective solvent as indicated in the individual experiments. The medium was 
changed daily.  
Cell viability/metabolic activity was determined by addition of WST-1 reagent (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer’s recommendations after 
incubation of the cells with 0.5 µg/ml PCL or 100 ng/ml BLP and also with 0.5 µg/ml pure PC 
(dissolved in ethanol/PBS 1:100) for 24 - 72 h as indicated in the respective experiments. 
Cell proliferation was measured after BrdU-pulsing for the last 24 h using a cell proliferation 
BrdU ELISA (Roche Diagnostics GmbH) on a microplate reader. For cell cycle analysis cells 
were resuspended in 100 % ice-cold ethanol and incubated at -20°C for at least 2 h. Afterwards 
the cells were centrifuged, washed and incubated with staining-solution (10 μg/ml propidium 
iodide; 100 μg/ml RNaseA in PBS) for 30 min at 37°C and analyzed on a BD LSR II flow 
cytometer. 
For AnnexinV staining, the cells were harvested using accutase (BD Biosciences). After washing 
with PBS, the cells were resuspended in 100 µl binding buffer (BD Pharmingen) and 2 µl 
Annexin V-FITC and incubated for 10 min in the dark. Thereafter the cells were incubated with 1 
µl To-Pro-3 Iodide (Invitrogen) for 5 min. Afterwards 200 µl binding buffer was added and the 
samples were measured on a BD FACSCalibur. 
For the BMDM migration assay 7.5 x 104 BMDM were seeded onto membrane-inserts 
(translucent track-etched polyethylene terephthalate (PET) membranes with 8µm pores, BD), and 
incubated for 18 h in a 24-well-plate (Companion plate, BD) in 300 µl medium, supplemented 
with either 0.5 µg/ml PCL or 100 ng/ml BLP or the respective solvent. Afterwards the membrane 
was separated and the cells were stained with 5 µM calcein for 1 h at 37 °C. After washing with 
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PBS and removing of cells on top of the membrane (BMDMs which had not migrated), the cells 
at the bottom of the membrane were analyzed on a microscope and counted with the help of the 
software ImageJ. 
 
Gene expression analysis 
Total RNA from tissue was isolated using TriReagent (Sigma-Aldrich, Taufkirchen, Germany). 
cDNA was synthesized using Superscript II and random hexamers (Invitrogen, Karlsruhe, 
Germany). Real time quantitative RT-PCR analysis was carried out using the ABI Prism HT 
7900 detection system instrument and software (Applied Biosystems, Darmstadt, Germany). 
Primer pairs used for expression analysis are shown in supplementary Table S1. The data was 
analyzed using the standard curve method for relative quantification. Levels of assayed genes 
were normalized to 18S rRNA expression. All samples were reverse transcribed and measured in 
two independent experiments in triplicates.  
 
FACS analyses of tissue macrophages 
FACS analysis of immune cells was performed on single cell suspensions of spleen and skin. For 
this purpose, splenocytes were isolated by squeezing the organ through a nylon mesh (40 µm) 
into a petri dish containing 10 ml PBS. Single cell suspensions of skin were obtained by 
dissecting the tumor-bearing ears into very small pieces with a scalpel. After digestion for 1 h at 
37°C in 2 ml HBSS containing 0.2% collagenase type-II (Worthington), the cells were filtered 
through a 70 µm nylon filter (BD Bioscience) and the collagenase was inactivated with 10% FCS 
in PBS. After a washing step at 400 g for 5 min cells were resuspended in PBS. Cells (1 x 106) 
were stained with monoclonal antibodies against CD11b (anti CD11b-FITC, #557396), Gr1 (anti 
Gr1-PE, #553128) and F4/80 (anti F4/80-Cy5, 15-4801), which were purchased from BD 
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Biosciences and eBiosciences, respectively. At least 10 x 103 viable cells were acquired on the 
basis of forward and side scattering and quantified by using a BD LSRII cytometer. Data 
acquisition and analysis were performed using the software BD FacsDiva (BD Biosciences 
Pharmingen) and FlowJo (Treestar, Ashland, OR), respectively.  
 
Measurement of cytokine production by ELISA 
BMDM (1.5 x 104 cells per well) were plated into 96-well-plates. The next day, the cells were 
stimulated with either 0.5 µg/ml PCL or 100 ng/ml BLP or the respective solvent. The 
supernatant was harvested after 24 h. IL-6, IL-10, MCP-1/CCL2, MIP-1α/CCL3, Rantes/CCL5 
and KC/CXCL1 were measured using DuoSet ELISA Development Kits (R&D Systems GmbH, 
Wiesbaden). TNF-α or IL-12p40 were quantified using ELISA kits from BioLegend (San Diego, 
CA, USA) and eBioscience (San Diego, CA, USA), respectively [24]. 
 
Statistical analyses 
If not otherwise indicated, statistical differences were analyzed using Mann-Whitney testing or 
Student’s t-test. Data was considered significant when P < 0.05. 
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Results 
Systemic application of both PCL and BLP results in tumor growth inhibition in a mouse 
model of BCC  
When analysing the antitumor effects of PCL-encapsulated drugs, we made the unexpected 
observation that the application of PCL resulted in growth inhibition of BCC in mice. To study 
this phenomenon in more detail, we induced BCC in PtchfloxfloxERT2+/- mice and systemically 
applied PBS, PCL or BLP starting from day 15 after BCC induction. BLP was used as a control 
substance because it is known to inhibit growth of other tumors in mice [18]. All compounds 
were applied i.p. every fourth day until day 90 following tumor induction, when mice were 
sacrificed. Histological analysis of the tumor-bearing skin revealed that tumors of solvent-treated 
mice were larger when compared to both PCL- and BLP-treated mice (Fig. 1A). This was also 
evident when the tumor area was calculated using the area calculation tool of the software cellF. 
Indeed, the differences between solvent- and PCL- or BLP-treated animals were significant (Fig. 
1B). These data show that similar to BLP, PCL treatment results in inhibition of tumor growth in 
the PtchfloxfloxERT2+/- mouse model for BCC. 
 
Systemic application of both PCL and BLP decreases the numbers of tissue macrophages   
Because tumor growth frequently depends on macrophage infiltration, we first investigated 
whether systemically applied PCL and BLP had a general effect on the number of macrophages 
or on related cells derived from the myeloid lineage. For this purpose we counted the numbers of 
immune cells isolated from the spleens of PBS-, PCL- or BLP-treated mice. Furthermore, we 
investigated the numbers of tumor-associated macrophages (TAM) in the tumor-bearing skin in 
the same cohorts. Single-cell suspensions derived from these tissues were stained with antibodies 
directed against Mac1 (CD11b) and F4/80. Whereas Mac1 is expressed on granulocytes, T-, B- 
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and natural killer (NK)-cells, dendritic cells and monocytes [25], murine macrophages 
additionally express F4/80 [26].  
Compared to PBS-treated mice, the PCL treatment resulted in a significant decrease of Mac1+, 
F4/80+ and Mac1+F4/80+ cells in the spleen (Table 1). This was similar to BLP treatment, which 
equally decreased these cell subpopulations. A moderate reduction of these cells was also 
observed in the skin, however within statistical variance (Table 1).  
Together, these data demonstrate that systemic PCL- or BLP-treatment results in reduction of 
macrophages in the spleen and possibly also in the skin, indicating a change in the tumor 
microenvironment. 
 
Systemic PCL application in tumor-bearing mice results in a gene expression profile 
different to that induced by BLP  
To investigate possible changes in the tumor microenvironment we analyzed typical macrophage 
markers in the tumor-bearing skin. These were the M1-specific markers Cxcl10 and iNOS and the 
M2-specifc markers Arg1 and Trem2. In comparison to the control group, BLP significantly 
augmented iNOS and Cxcl10, whereas PCL significantly increased the expression of iNOS and 
also the M2 markers Arg1 and Trem2 (Fig. 2A). These data suggest that BLP induced a M1 
phenotype, whereas PCL administration induced a more M2-like phenotype. To test whether the 
moderate decrease in macrophage infiltration after PCL or BLP treatment in BCC-bearing skin is 
associated with altered expression of chemokine receptors, we analyzed the expression of the 
chemokine receptors Ccr2 and Ccr5. These receptors have been shown to be involved in the 
trafficking of monocytes/macrophages [27,28] and downregulation could explain the moderately 
reduced macrophage abundance in BCC. However, the analysis of Ccr2 and Ccr5 expression 
revealed upregulation of both genes in the treated BCC-bearing skin (PCL 26fold and 12fold and 
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BLP 14fold and 4fold for Ccr2 and Ccr5, respectively; Fig. 2B). The upregulation after BLP-
treatment was significant for Ccr2, whereas significance was reached for both genes after PCL 
treatment. To rule out that increased expression levels of Ccr2 and Ccr5 were caused by 
infiltrating T cells, we counted CD3-positive cells on tumor sections stained with an appropriate 
antibody. However, the infiltration with T cells was not different between the treatment groups 
(data not shown). Collectively, these data indicate a change of the tumor microenvironment after 
BLP- and PCL-treatments that particularly involves a change in the phenotype of TAM. 
 
Similar to BLP, PCL inhibit proliferation, induce apoptosis and enhance the migratory 
capacity of BMDM  
To exclude that BLP or PCL suppress tumor cells by direct tumoricidal activity as observed with 
e.g. TLR3 agonists [29], we investigated the effects of both compounds on BCC cells in vitro. 
For this purpose, the BCC cell line ASZ001 was incubated with 0.5 µg/ml of PCL for 72 h. BLP 
was applied at a concentration of 100 ng/ml. Neither PCL nor BLP affected the level of BrdU 
incorporation in these cells (Supplementary Fig. S1A). The treatments also did not change the 
numbers of Annexin V+ ASZ001 cells (Supplementary Fig. S1B). Finally we also investigated 
the tumoricidal activity of pure PC by analyzing the toxicity of 0.5 µg/ml PC. However, pure PC 
also did not impact on viability of ASZ001, although it was used at a slightly higher 
concentration than the PC present in 0.5 µg/ml PCL (Supplementary Fig. S2). These data indicate 
that neither PCL nor BLP exerted direct tumoricidal activity and did not inhibit proliferation or 
survival of BCC cells.  
As shown above, PCL and BLP induce changes in the expression of macrophage markers in 
tumor-bearing skin suggesting an impact of both substances on the TAM phenotype. Hence, we 
characterized the effects of PCL and BLP on macrophages in vitro. For this purpose, we 
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generated BMDM and cultured them in the presence or absence of 0.5 µg/ml of PLC or 100 
ng/ml of BLP. PBS was used as a vehicle control.  
As shown in Figure 3A, BLP treatment resulted in larger cells exhibiting a swollen cell body 
resembling the phenotype of LPS-activated BMDM [30]. In contrast, after treatment with PCL 
BMDM preserved the general cellular shape compared to control cells. Consistently, the WST 
assay measuring cell viability and metabolic activity revealed that BLP significantly enhanced 
the metabolic activity of BMDM, whereas the increase after PCL treatment was not significant 
(Fig. 3B).  
We then analyzed the proliferative capacity of BMDM after treatment with PCL or BLP. BMDM 
were incubated for 72 h with the compounds. As revealed by the BrdU incorporation assay, both 
PCL and BLP significantly reduced BMDM proliferation (Fig. 3C). A cell cycle analysis showed 
that PCL treatment caused a cell cycle arrest at the G1/S boundary, because the percentage of 
PCL-treated BMDM in the S phase was significantly lower and the fraction of cells in the G0/G1 
phase was significantly higher, relative to PBS-treated BMDM (Table 2). In contrast, BLP seem 
to induce an arrest at the G1/S as well at G2/M boundaries, because treatment significantly 
decreased the cell numbers in the S phase and additionally increased the number of cells in the 
G2/M phase (Table 2). These data indicate that PCL and BLP arrest BMDM proliferation in 
different phases of the cell cycle. 
The effects of PCL and BLP on BMDM apoptosis were investigated by FACS analysis of 
Annexin V/PI-stained cells. As demonstrated in Figure 3D, both treatments resulted in a 
significant increase of Annexin V+ cells. However, the degree of apoptotic cells was higher with 
BLP than with PCL treatment (26% versus 13% Annexin V+ cells, respectively) (Fig. 3D). When 
we distinguished between early (Annexin V+/PI-) and late (Annexin V+/PI+) apoptotic cells, we 
found that both compounds increased either of these cellular subsets in a similar fashion (data not 
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shown). These results suggest that PCL induce apoptosis of BMDM. This is similar to BLP that 
is known for its proapoptotic activity on the monocytic cell line THP-1 [31].  
Together these findings suggest that both PCL and BLP inhibit survival and proliferation of 
BMDM, while keeping the cells in a state of high metabolic activity.  
Finally, we analyzed the migratory capacity of PCL- and BLP-treated BMDM. As shown in 
Figure 3E, both substances enhanced the migratory capacity and the effect was significant for 
PCL (Fig. 3E).  
 
PCL do not induce cytokine secretion in BMDM  
So far the results showed that PCL treatment switches the TAM phenotype, decreases the 
survival and proliferative capacity of macrophages, but results in an increased migratory capacity. 
The latter finding, together with the high metabolic activity of the BMDM (see Fig. 3B), 
prompted us to investigate whether PCL induced the secretion of cytokines in BMDM. 
Surprisingly and in contrast to BLP, PCL did not induce cytokine production. BLP induced 
Rantes/CCL5 and KC/CXCL1, factors known as chemoattractants of neutrophils, immature 
dendritic cells, NK cells, and activated T cells [32]. Further, BLP-treated BMDM produced the 
pro-inflammatory cytokines TNFα and MCP-1/CCL2, the latter being involved in migration of 
monocytes, memory T lymphocytes and natural killer cells [33]. BLP-treated BMDM also 
secreted IL-6, IL-10, IL-12p40 and MIP-1α/CCL3. All these proteins were not detected in the 
supernatant of PCL-treated BMDM or were not elevated beyond solvent-treatment (Fig. 4A). 
Hence, the impact of BLP and PCL on proliferation, migration and apoptosis is apparently not 
related to these cytokines implying that the impact of BLP and PCL on the functional behavior of 
BMDM is not intimately coupled to a concomitant organization of a cyto/chemokine release 
spectrum. 
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PCL and BLP induce different macrophage phenotypes  
To further support the in vivo data shown in figure 2, we incubated BMDM with either PCL or 
BLP and measured the expression of M1 and M2 markers. In BMDM, both PCL and BLP 
significantly inhibited expression of the M1-specific marker Cxcl10. PCL also inhibited iNOS 
expression, whereas iNOS was upregulated by BLP. The expression levels of the M2-specific 
markers Arg1 or Trem2 were upregulated or downregulated, respectively, by BLP. In contrast, 
PCL-treatment resulted in a significant upregulation of Trem2, whereas the expression level of 
Arg1 remained unchanged (Fig. 4B). These data indicate that PCL or BLP induce different 
macrophage phenotypes. Second, the in vivo situation seems to be more complex than the in vitro 
situation, because TAM showed a different expression of M1/M2 markers after treatment 
compared to BMDM. This could be due to the particular composition of the tumor 
microenvironment. Finally, the distinct expression profiles induced by either compound both in 
vivo and in vitro indicate that the inhibition of tumor growth cannot be assigned to a simple 
phenotypic macrophage orientation and must have been provoked by alternative mechanisms. 
Most importantly, however, PCL as commonly used drug encapsulation tool deliver their own 
intrinsic tumor-cell-targeted activity. 
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Discussion 
Our data show that the systemic application of empty PCL induces an antitumor response against 
BCC in mice. The antitumor response is similar to that achieved by BLP, although the response 
of TAM to either compound seems to be different. 
The antitumor activity of TLR2 agonists is well known. Indeed, TLR2 agonists can be beneficial 
in the prevention of cancer relapse and the therapeutic effects of Bacillus Calmette-Guerin 
(BCG), which is used in the treatment of human bladder cancer, is mainly TLR2 mediated [34]. 
During the last years it has emerged that BLP induces an immunotherapeutic activity on a variety 
of tumors in mice [18]. Zhang and colleagues showed that the antitumor effect of BLP was not 
mediated by direct tumoricidal activity. This is similar to the findings in our study, in which 
apoptosis and proliferation of tumor cells were not influenced by BLP. The authors showed that 
the anticancer effects of BLP involved a reduction of the suppressive function of Foxp3-
expressing regulatory T cells (Tregs) and a concomitant enhancement of the cytotoxicity of 
tumor-specific CTL in vitro and in vivo. Because BLP lacked an antitumor effect in immune 
deficient SCID mice, the authors concluded that the BLP-mediated tumor remission was not 
mediated by innate immune cells [18]. T his is in contrast to our observations. Admittedly, we 
have not investigated the function of T cell populations in our setting. Although these cells may 
have contributed to the antitumor activity of BLP in our experiments, our data suggest an 
additional involvement of macrophages. This assumption is based on the BLP-induced reduction 
of macrophages numbers in the in vivo setting. Indeed, BLP also exerted a strong antiproliferative 
and proapoptotic effect on macrophages in culture and induced cell cycle arrest. In addition, BLP 
treatment modulated the expression of M1- and/or M2-markers in vivo and in vitro.  
Importantly, our data show that already empty PCL modulate innate immune cells and inhibit 
tumor growth. This is surprising because the antitumor effects of empty PCL reported so far were 
18 
 
insignificant in both immune-deficient and immune-competent mice [19,35]. However, because 
the tumors and tumor cell lines used in these studies were fast-growing, it is possible that 
differences in tumor growth and progression after PCL treatment have been overlooked. Indeed, a 
moderate tumor growth inhibition after PCL treatment is demonstrated in the work of Zeisberger 
and colleagues, who used the teratocarcinoma F9 cells to study antitumor effects of PCL-
encapsulated drugs [19]. In addition, one recent report described antimetastatic activity of PCL in 
a mouse model of pancreatic cancer. Since the PCL used in the latter study contained fully 
hydrogenated palmitic and stearic fatty acids, the authors ascribed the antimetastatic activity in 
their model to these particular lipids. They also discussed the potential influence of these fatty 
acids on lipid metabolism, which could impede the generation of lipid second messengers being 
crucial for the metastatic process [10]. However, the PCL used in our study did not contain 
hydrogenated fatty acids. This excludes the possibility that hydrogenated fatty acids were 
responsible for its antitumor effects. Our data also strongly argues against a role of pure PC in the 
antitumor effects of PCL. Indeed, Sakakima and colleagues demonstrated that PC by itself is able 
to directly induce the inhibition of the growth of hepatic cancer cells. Furthermore, intragastrical 
administration of PC significantly reduced the number of macroscopic hepatic tumor nodules in 
rats submitted to hepatocarcinogenesis by diethylnitrosamine and phenobarbital co-
administration [36]. Additionally, other authors demonstrated that PC induces apoptosis in 
different cell lines such as colon cancer cells [37], vascular endothelial cells [38] and 3T3-L1 pre-
adipocytes [39]. However, the fact that the viability of the BCC cell line ASZ001 was not altered 
by PC indicates that this substance probably was not the cause for the antitumor effects of PCL in 
the BCC mouse model. Because PCL in our experiments was applied intraperitoneally, we also 
can exclude metabolism of PC by microbes of the gut, which has been reported to result in the 
formation of deleterious catabolites that equally could have inhibited tumor growth [40].  
19 
 
Currently it is believed that the innate immune system is not affected by liposomes [41,42]. 
Indeed, PCL do not induce cytokine production of bone marrow derived cells in culture (as found 
in this study and as described by Faisal et al. [43]), which is in support of this assumption. 
However, our results also revealed that PCL substantially decrease the number of splenic and 
tumor-associated macrophages. This data suggest that PCL directly affect these cell populations. 
Indeed, intravenously injected liposomes are mainly found in macrophages of the spleen, in 
macrophages in inflamed tissue [44] and in tumor-associated macrophages [19,45]. Thus, our 
data suggest that application of PCL may have an impact on the innate immune system by 
affecting survival or proliferation of these cells. On the hand it is possible that PCL reduced the 
recruitment of macrophages to the tumor cells in our setting. The proapoptotic and 
antiproliferative effects of PCL on cultured macrophages as well as the increased migratory 
capacity of PCL-treated BMDM support both assumptions. Furthermore, PCL seem to modulate 
expression of markers specific for both the M1 and M2 type of macrophages: in contrast to BLP, 
which induced a significant M1-biased expression pattern i.e. iNOS and Cxcl10, PCL also 
resulted in a significant upregulation of Arg1 and Trem2 in the tumor-bearing skin. Because the 
expression of these genes was not induced in ASZ001 (data not shown), and because Arg1 and 
Trem2 are specifically expressed by macrophages [46,47], the PCL treatment apparently also 
trigger a phenotype switch towards TAM of an alternatively activated phenotype in the tumor-
bearing skin. Although M2 macrophages in general are thought to promote tumor-progression at 
least in vitro, TAM can have a very variable phenotype and their relative abundance varies with 
the tumor type. For example, macrophages with neither M1 nor M2 characteristics have been 
identified in mammary tumor models. Moreover, the macrophage phenotype also varies in 
different areas of a tumor. It also can depend on the applied anticancer drugs. These studies 
emphasize the plasticity and heterogeneity of macrophage functional states and indicate that 
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typical M1 and M2 phenotypes are extremes of a broad spectrum of functional states (reviewed in 
[15,45]). The effects of PCL and BLP on the expression of M1- and M2-specific markers were 
also different on BMDM in culture. In addition, the expression of these markers differed 
substantially between TAM in vivo and BMDM in vitro. The most obvious explanation for latter 
discrepancy is the fact that TAM interact with many other cellular components, such as tumor 
cells, epithelial cells, B and T cells or fibroblasts [48]. All these cells may govern functional 
adjustments in TAM in vivo but are absent in BMDM cultures. Conceivably, Ccr2 and Ccr5 
could be involved in the recruitment of e.g. T and B cells as both chemokines regulate trafficking 
of these cells [49,50]. However, a first analysis indicates that T cell trafficking may not be 
affected by the compounds tested.  
Collectively our data demonstrate that the application of empty liposomes has antitumor activity 
in a mouse model of BCC. Furthermore, our data suggest that the antitumor activity of PCL is 
mediated by the tumor microenvironment, in particular by TAM. As resident immune and tumor-
associated cells, they are capable of liposome phagocytosis, which in turn can apparently 
influence a whole variety of processes within the tumor microenvironment. Although the exact 
mechanisms remain to be established, PCL-mediated antitumor effects correlate with a 
macrophage phenotype different from that induced by BLP. However, most important is the 
finding that application of empty PCL alters function and phenotype of macrophages which 
should be considered when PCL are used as drug delivery systems. 
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Figure legends 
Figure 1: Systemic application of PCL and BLP results in growth inhibition of BCC in 
Ptchflox/floxERT2+/− mice. (A) HE-stained skin sections and (B) relative tumor areas of HE-
stained BCC of solvent-, PCL- or BLP-treated mice. The solvent-treated control was normalized 
to 1. Data represent mean ± SEM. *P < 0.05 by Mann-Whitney-U testing. 
 
Figure 2: Systemic application of PCL results in a gene expression profile different to that 
induced by BLP in BCC-bearing skin. Gene expression was measured by qRT-PCR. (A) 
Cxcl10, iNOS, Arginase1, Trem2 and (B) Ccr2 and Ccr5 in BCC-bearing skin from solvent-, 
PCL- or BLP-treated mice. Values of solvent-treated controls were normalized to 1. Data 
represent mean ± SEM of at least three independent experiments performed in triplicates. *P < 
0.05 by Mann-Whitney-U testing. 
 
Figure 3: PCL and BLP inhibit proliferation, induce apoptosis and enhance the migratory 
capacity of BMDM. (A) Phenotypic appearance of BMDM after incubation with PBS, PCL or 
BLP for 72 h. (B) Metabolic activity of PBS-, PCL- or BLP-treated BMDM as measured by a 
WST-1 assay. Values of solvent-treated controls were set to 100 %. (C) BrdU incorporation 
shown as percentage of respective solvent-treated controls and (D) Annexin V+ cells after 
treatment with PBS, PCL or BLP for 72 h. (E) Migratory capacity of BMDM shown as 
percentage of the values obtained with solvent-treated controls. Data represent mean ± SEM of at 
least three independent experiments as performed in duplicates. *P < 0.05 by Mann-Whitney-U 
testing. 
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Figure 4: In contrast to BLP, PCL alter the phenotype of BMDM without inducing cytokine 
release. (A) Cytokine concentrations were measured by ELISA in BMDM culture supernatants 
after treatment with solvent, PCL or BLP. (B) qRT-PCR analysis of the M1-specific markers 
Cxcl10 and iNOS and of the M2-specific markers Arg1 and Trem2 in RNA isolated from solvent-
, PCL- or BLP-treated BMDM. Values of solvent-treated controls were set to 1. Data represent 
mean ± SEM of at least two independent experiments performed in triplicates. *P < 0.05 by 
Mann-Whitney-U testing. 
 
 
 
 
 
 
Table 1: Systemic application of PCL and BLP decreases the numbers of tissue 
macrophages. The percentage of Mac1+, F4/80+ and Mac1+F4/80+ double-positive cells in 
spleen and in tumor-bearing skin of Ptchflox/floxERT2+/− mice was determined by FACS. * P < 
0.05 by Student’s t-test. 
 
Treatment 
Spleen 
Positive cells in % (± SEM) 
Mac1 F4/80 Mac1_F4/80 
PBS 4,89 (0,30) 0,52 (0,08) 0,51 (0,08) 
PCL    3,50 (0,33) *    0,29 (0,01) *   0,26 (0,02) * 
BLP    3,05 (0,06) *    0,24 (0,01) *   0,23 (0,02) * 
Treatment 
BCC-bearing skin 
Positive cells in % (± SEM) 
Mac1 F4/80 Mac1_F4/80 
PBS 4,92 (0,58) 3,31 (0,10) 3,06 (0,11) 
PCL 3,16 (0,47) 3,29 (0,39) 2,38 (0,29) 
BLP 3,67 (0,62) 3,09 (0,39) 2,33 (0,29) 
 
 
 
 
 
Table 2: Treatment of BMDM with PCL causes cell cycle arrest in the G1/S phase. 
BMDM were incubated with the compounds or solvent for 72 h, stained with propidium 
iodide and analyzed by FACS. *P < 0.05 by Student’s t-test. 
Treatment G0/G1 S-phase G2/M 
Counts in % (± SEM) 
PBS 58,20 (1,95)  26,00 (0,77) 11,30 (0,95) 
PCL   73,50 (1,44) *    11,90 (1,17) * 11,40 (0,37) 
BLP 62,00 (0,90)   13,20 (0,21) *   15,00 (0,30) * 
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Supplementary Table S1: Oligonucleotides used for quantitative RT-PCR 
 
 
Primer Name Primer Sequence (5’-3’ orientation) Application 
mArginase1_F TGGCTTGCGAGACGTAGAC murine Arg1 expression 
analysis mArginase1_R GCTCAGGTGAATCGGCCTTTT 
mCcr2_F1 GCCATGCAAGTTCAGCTGCCTGC 
 
murine Ccr2 expression 
analysis mCcr2_R CCATCATCGTAGTCATACGGTG 
mCcr5_F CAGCTCTCCTAGCCAGAGGAG 
 
murine Ccr5 expression 
analysis mCcr5_R GGCAGGAGCTGAGCCGCAATTTG 
mCXCL10_F CCAAGTGCTGCCGTCATTTTC murine Cxcl10 
expression analysis mCXCL10_R GGCTCGCAGGGATGATTTCAA 
iNOS_F GTTCTCAGCCCAACAATACAAGA murine iNOS expression 
analysis iNOS_R GTGGACGGGTCGATGTCAC 
mTrem2_F CTGGAACCGTCACCATCACTC murine Trem2 
expression analysis mTrem2_R CGAAACTCGATGACTCCTCGG 
18S-fwd CGCAAATTACCCACTCCCG murine 18s expression 
analysis 18S-rev2 TTCCAATTACAGGGCCTCGAA 
  
Figure S1  
     
 
Supplementary Figure S1: Neither PCL nor BLP inhibit proliferation or survival of 
BCC cells. The BCC cells ASZ001 were incubated with either 0.5 µg/ml PCL, 100 ng/ml 
BLP or PBS for 72 h. (A) BrdU incorporation as percentage of respective vehicle-treated 
controls and (B) percentage of Annexin V positive cells. 
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Figure S2 
 
 
Supplementary Figure S2: PC did not affect viability of BCC cells. The BCC cell line 
ASZ001 was incubated with either 0.5 µg/ml PCL or 0.5 µg/ml PC or the respective solvent 
(PBS or ethanol/PBS 1:100, respectively) for 72 h and cell viability/metabolic activity of the 
cells was measured as described in the material and methods section. Mean values of the 
solvent-treated controls were set to 100 %. Data represent mean ± SEM of at least 2 
independent experiments performed in triplicates.  
